FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2193664146> ?p ?o ?g. }

• W2193664146 endingPage "7" @default.
• W2193664146 startingPage "3961" @default.
• W2193664146 abstract "Dabigatran is a novel target specific oral anticoagulant for stroke prevention in non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety in the italian population. Aim of our study was to evaluate the efficacy and safety of dabigatran in a large single-center cohort of real-life italian population with non-valvular AF and to compare the results with those obtained from the RE-LY trial and the Medicare study.We studied a prospective cohort of 2108 patients (1119 male; mean age 69.4 ± 9.4 years) who started the oral anticoagulant treatment with dabigatran 110 mg twice-daily (DAB 110; N = 1075; 51%) or 150 mg twice-daily (DAB 150; N = 1033; 49%). Follow-up data were obtained trough outpatients visits each 3-6 months for assessing the clinical status, adherence to treatment, occurrence of side effects and major cardiovascular complications.In DAB 150 group the mean age was 64.9 ± 8.8 years, 56.8% of patients was male. CHA2DS2Vasc Score was ≥ 3 in 94.3% and HAS-BLED was ≥ 3 in 59.7%. In DAB 110 group (N = 1075) the mean age was 73.9 ± 7.5 years; 49.5% of patients was male. CHA2DS2Vasc Score was ≥ 3 in 73.4% and HAS-BLED was ≥ 3 in 87.4% of DAB 110 patients. One patient taking Dabigatran 110 mg bid had ischemic stroke without significantly neurological sequelae. In both groups, no patient experienced hemorrhagic stroke during the follow-up period. 147 patients (6.9%) of MonaldiCare population reported adverse effects from treatment with dabigatran, of whom 121 patients (5.7%) discontinued therapy. We reported one case of subarachnoid hemorrhage (0.05%) in a patient with high thrombo-embolic and high hemorrhagic risk score who was taking dabigatran 150 mg bid and one case (0.05%) of bladder bleeding in a patient who was taking dabigatran 110 mg bid. No major gastrointestinal bleeding was observed in the MonaldiCare population.MonaldiCare registry showed a safety profile of both dosages of dabigatran regarding major of fatal bleeding in a real life single center italian population at high thromboembolic and hemorrhagic risk. The majority of MonaldiCare patients tolerated dabigatran treatment without significant side effects. The efficacy of dabigatran was demonstrated by very low prevalence of ictus/TIA, also when patients underwent electrical AF cardioversion independently of the transesophageal examination." @default.
• W2193664146 created "2016-06-24" @default.
• W2193664146 creator A5000200390 @default.
• W2193664146 creator A5000558334 @default.
• W2193664146 creator A5012354435 @default.
• W2193664146 creator A5015966822 @default.
• W2193664146 creator A5032997213 @default.
• W2193664146 creator A5050522038 @default.
• W2193664146 creator A5056810264 @default.
• W2193664146 creator A5065463990 @default.
• W2193664146 creator A5073333080 @default.
• W2193664146 creator A5076951922 @default.
• W2193664146 date "2015-10-01" @default.
• W2193664146 modified "2023-10-14" @default.
• W2193664146 title "Efficacy and safety of dabigatran in a real-life population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry." @default.
• W2193664146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26531286" @default.
• W2193664146 hasPublicationYear "2015" @default.
• W2193664146 type Work @default.
• W2193664146 sameAs 2193664146 @default.
• W2193664146 citedByCount "15" @default.
• W2193664146 countsByYear W21936641462016 @default.
• W2193664146 countsByYear W21936641462017 @default.
• W2193664146 countsByYear W21936641462018 @default.
• W2193664146 countsByYear W21936641462019 @default.
• W2193664146 countsByYear W21936641462020 @default.
• W2193664146 countsByYear W21936641462021 @default.
• W2193664146 crossrefType "journal-article" @default.
• W2193664146 hasAuthorship W2193664146A5000200390 @default.
• W2193664146 hasAuthorship W2193664146A5000558334 @default.
• W2193664146 hasAuthorship W2193664146A5012354435 @default.
• W2193664146 hasAuthorship W2193664146A5015966822 @default.
• W2193664146 hasAuthorship W2193664146A5032997213 @default.
• W2193664146 hasAuthorship W2193664146A5050522038 @default.
• W2193664146 hasAuthorship W2193664146A5056810264 @default.
• W2193664146 hasAuthorship W2193664146A5065463990 @default.
• W2193664146 hasAuthorship W2193664146A5073333080 @default.
• W2193664146 hasAuthorship W2193664146A5076951922 @default.
• W2193664146 hasConcept C126322002 @default.
• W2193664146 hasConcept C127413603 @default.
• W2193664146 hasConcept C141071460 @default.
• W2193664146 hasConcept C187212893 @default.
• W2193664146 hasConcept C188816634 @default.
• W2193664146 hasConcept C2776301958 @default.
• W2193664146 hasConcept C2778205648 @default.
• W2193664146 hasConcept C2778661090 @default.
• W2193664146 hasConcept C2778810321 @default.
• W2193664146 hasConcept C2779161974 @default.
• W2193664146 hasConcept C2780645631 @default.
• W2193664146 hasConcept C2908647359 @default.
• W2193664146 hasConcept C71924100 @default.
• W2193664146 hasConcept C72563966 @default.
• W2193664146 hasConcept C78519656 @default.
• W2193664146 hasConcept C99454951 @default.
• W2193664146 hasConceptScore W2193664146C126322002 @default.
• W2193664146 hasConceptScore W2193664146C127413603 @default.
• W2193664146 hasConceptScore W2193664146C141071460 @default.
• W2193664146 hasConceptScore W2193664146C187212893 @default.
• W2193664146 hasConceptScore W2193664146C188816634 @default.
• W2193664146 hasConceptScore W2193664146C2776301958 @default.
• W2193664146 hasConceptScore W2193664146C2778205648 @default.
• W2193664146 hasConceptScore W2193664146C2778661090 @default.
• W2193664146 hasConceptScore W2193664146C2778810321 @default.
• W2193664146 hasConceptScore W2193664146C2779161974 @default.
• W2193664146 hasConceptScore W2193664146C2780645631 @default.
• W2193664146 hasConceptScore W2193664146C2908647359 @default.
• W2193664146 hasConceptScore W2193664146C71924100 @default.
• W2193664146 hasConceptScore W2193664146C72563966 @default.
• W2193664146 hasConceptScore W2193664146C78519656 @default.
• W2193664146 hasConceptScore W2193664146C99454951 @default.
• W2193664146 hasIssue "20" @default.
• W2193664146 hasLocation W21936641461 @default.
• W2193664146 hasOpenAccess W2193664146 @default.
• W2193664146 hasPrimaryLocation W21936641461 @default.
• W2193664146 hasRelatedWork W1972269502 @default.
• W2193664146 hasRelatedWork W2006773714 @default.
• W2193664146 hasRelatedWork W2021252689 @default.
• W2193664146 hasRelatedWork W2119748408 @default.
• W2193664146 hasRelatedWork W2434927469 @default.
• W2193664146 hasRelatedWork W2509901103 @default.
• W2193664146 hasRelatedWork W2796691103 @default.
• W2193664146 hasRelatedWork W2979702411 @default.
• W2193664146 hasRelatedWork W2990629389 @default.
• W2193664146 hasRelatedWork W3370658 @default.
• W2193664146 hasVolume "19" @default.
• W2193664146 isParatext "false" @default.
• W2193664146 isRetracted "false" @default.
• W2193664146 magId "2193664146" @default.
• W2193664146 workType "article" @default.